Sign up USA
Proactive Investors - Run By Investors For Investors

Catabasis surges after successful mid-stage trial of its DMD treatment

Catabasis’ edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed
boy walking on beach
DMD almost exclusively affects young boys and there is current no known cure

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) surged on Tuesday after the biopharma reported positive results from a mid-stage study of its Duchenne muscular dystrophy treatment.

In the trial, the company’s edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed.

Consistent improvements in all assessments of muscle function were observed after more than a year of treatment compared to the rate of change in the pre-specified control period.

DMD is a rare muscle-wasting disease that almost exclusively affects only young boys, for which there is currently no known cure.

Importantly, Catabasis is looking to treat all DMD sufferers with edasalonexent rather than just a subset of patients.

A pivotal phase III trial is scheduled to get underway in the first half of this year, with top-line data expected in 2020.

“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said chief executive Jill Milne.

“Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease.”

Catabasis shares soared by a quarter to US$1.57 on Tuesday.

View full CATB profile View Profile

Catabasis Pharma Timeline

Related Articles

cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use